Faunce Thomas A
College of Law and Medical School, Australian National University, Canberra, Australia.
Aust New Zealand Health Policy. 2007 Jun 1;4:9. doi: 10.1186/1743-8462-4-9.
Industrial renewal in the bio/nanopharma sector is important for the long term strength of the Australian economy and for the health of its citizens. A variety of factors, however, may have caused inadequate attention to focus on systematically promoting domestic generic and small biotechnology manufacturers in Australian health policy. Despite recent clarifications of 'springboarding' capacity in intellectual property legislation, federal government requirements for specific generic price reductions on market entry and the potential erosion of reference pricing through new F1 and F2 categories for the purposes of Pharmaceutical Benefits Scheme (PBS) assessments, do not appear to be coherently designed to sustainably position this industry sector in 'biologics,' nanotherapeutics and pharmacogenetics. There also appears to have been little attention paid in this context to policies fostering industry sustainability and public affordability (as encouraged by the National Medicines Policy). One notable example includes that failure to consider facilitating mutual exchanges on regulatory assessment of health technology safety and cost-effectiveness (including reference pricing) in the context of ongoing free trade negotiations between Australia and China (the latter soon to possess the world's largest generic pharmaceutical manufacturing capacity). The importance of a thriving Australian domestic generic pharmaceutical and bio/nano tech industry in terms of biosecurity, similarly appears to have been given insufficient policy attention.Reasons for such policy oversights may relate to increasing interrelationships between generic and 'brand-name' manufacturers and the scale of investment required for the Australian generics and bio/nano technology sector to be a significant driver of local production. It might also result from singularly effective lobbying pressure exerted by Medicines Australia, the 'brand-name' pharmaceutical industry association, utilising controversial interpretations of reward of pharmaceutical 'innovation' provisions in the Australia-US Free Trade Agreement (AUSFTA) through the policy-development mechanisms of the AUSFTA Medicines Working Group and most recently an Innovative Medicines Working Group with the Department of Health and Ageing. This paper critically analyses such arguments in the context of emerging challenges for sustainable industrial renewal in Australia's bio/nanopharma sector.
生物/纳米制药领域的产业复兴对于澳大利亚经济的长期实力及其公民的健康至关重要。然而,多种因素可能导致在澳大利亚的卫生政策中,对系统促进国内仿制药和小型生物技术制造商的关注不足。尽管最近在知识产权立法中对“跳板”能力进行了澄清,但联邦政府对仿制药进入市场时特定降价的要求,以及在药品福利计划(PBS)评估中通过新的F1和F2类别对参考定价的潜在侵蚀,似乎并非旨在连贯地将该行业可持续定位在“生物制剂”、纳米治疗学和药物遗传学领域。在这方面,对于促进产业可持续性和公众可承受性的政策(如国家药品政策所鼓励的)似乎也很少关注。一个显著的例子是,在澳大利亚与中国正在进行的自由贸易谈判(中国即将拥有世界上最大的仿制药生产能力)背景下,未能考虑促进关于卫生技术安全性和成本效益(包括参考定价)监管评估的相互交流。同样,澳大利亚国内蓬勃发展的仿制药和生物/纳米技术产业在生物安全方面的重要性,似乎也未得到足够的政策关注。
此类政策疏忽的原因可能与仿制药制造商和“品牌药”制造商之间日益增强的相互关系,以及澳大利亚仿制药和生物/纳米技术部门成为本地生产重要驱动力所需的投资规模有关。这也可能是由于澳大利亚药品行业协会“品牌药”行业协会通过澳美自由贸易协定(AUSFTA)药品工作组以及最近与卫生与老龄部的创新药品工作组的政策制定机制,对澳美自由贸易协定中制药“创新”奖励条款进行有争议的解释而施加的异常有效的游说压力所致。本文在澳大利亚生物/纳米制药行业可持续产业复兴面临的新挑战背景下,对这些论点进行了批判性分析。